Subscribe To
Esperion therapeutics stock slumps 22% premarket as data from study of cholestrol-lowering drug fail to impress investors
The stock of Esperion Therapeutics Inc. ESPR, -0.31% slumped 22% in premarket trade Monday, as investors seemed to question whether data from a major ...
March 6, 2023, 6:52 am
Verve therapeutics: verve-101 on hold, but technology remains sound
Verve Therapeutics is a gene editing company focused on revolutionizing the treatment of cardiovascular...
March 5, 2023, 4:46 pm
Amarin announces new reduce-it® data at acc.23/wcc showing benefit of vascepa®/vazkepa® (icosapent ethyl) in high-risk patients with a recent acute coronary syndrome event
–Post-Hoc Analysis Shows IPE Significantly Reduced Risk of First, Total Ischemic Events by 37% and 36% Respectively in Patients with Recent ACS With...
March 5, 2023, 3:21 pm
89bio presents new analysis of data from phase 2 entrigue trial of pegozafermin in patients with severe hypertriglyceridemia (shtg) at american college of cardiology’s annual scientific session togeth
– Post hoc analysis data demonstrated pegozafermin treatment significantly reduced triglycerides and other atherogenic lipids in patients with SHTG ...
March 4, 2023, 6:30 pm
89bio presents new analysis of data from phase 2 entrigue trial of pegozafermin in patients with severe hypertriglyceridemia (shtg) at american college of cardiology’s annual scientific session togeth
– Post hoc analysis data demonstrated pegozafermin treatment significantly reduced triglycerides and other atherogenic lipids in patients with SHTG ...
March 4, 2023, 6:30 pm
89bio presents new analysis of data from phase 2 entrigue trial of pegozafermin in patients with severe hypertriglyceridemia (shtg) at american college of cardiology’s annual scientific session togeth
– Post hoc analysis data demonstrated pegozafermin treatment significantly reduced triglycerides and other atherogenic lipids in patients with SHTG ...
March 4, 2023, 6:30 pm
89bio presents new analysis of data from phase 2 entrigue trial of pegozafermin in patients with severe hypertriglyceridemia (shtg) at american college of cardiology’s annual scientific session togeth
– Post hoc analysis data demonstrated pegozafermin treatment significantly reduced triglycerides and other atherogenic lipids in patients with SHTG ...
March 4, 2023, 6:30 pm
89bio presents new analysis of data from phase 2 entrigue trial of pegozafermin in patients with severe hypertriglyceridemia (shtg) at american college of cardiology’s annual scientific session togeth
– Post hoc analysis data demonstrated pegozafermin treatment significantly reduced triglycerides and other atherogenic lipids in patients with SHTG ...
March 4, 2023, 6:30 pm
New analyses of sotagliflozin showing time to clinical benefit presented at the american college of cardiology’s 72nd annual scientific session together with world heart federation’s world congress of
Statistically significant reduction in the risk for the primary outcome on Day 27 Findings generally consistent across the left ventricular ejection f...
March 4, 2023, 5:00 pm
New analyses of sotagliflozin showing time to clinical benefit presented at the american college of cardiology’s 72nd annual scientific session together with world heart federation’s world congress of
Statistically significant reduction in the risk for the primary outcome on Day 27 Findings generally consistent across the left ventricular ejection f...
March 4, 2023, 5:00 pm
New analyses of sotagliflozin showing time to clinical benefit presented at the american college of cardiology’s 72nd annual scientific session together with world heart federation’s world congress of
Statistically significant reduction in the risk for the primary outcome on Day 27 Findings generally consistent across the left ventricular ejection f...
March 4, 2023, 5:00 pm
New analyses of sotagliflozin showing time to clinical benefit presented at the american college of cardiology’s 72nd annual scientific session together with world heart federation’s world congress of
Statistically significant reduction in the risk for the primary outcome on Day 27 Findings generally consistent across the left ventricular ejection f...
March 4, 2023, 5:00 pm
Landmark clear outcomes study demonstrates nexletol® (bempedoic acid) tablet is the only ldl-c lowering therapy since statins to reduce hard ischemic events in a broad population of both primary preve
Results Demonstrate Significant Reductions in LDL-C, hsCRP and cardiovascular Risk in Patients Who Are ...
March 4, 2023, 3:30 pm
Landmark clear outcomes study demonstrates nexletol® (bempedoic acid) tablet is the only ldl-c lowering therapy since statins to reduce hard ischemic events in a broad population of both primary preve
Results Demonstrate Significant Reductions in LDL-C, hsCRP and cardiovascular Risk in Patients Who Are ...
March 4, 2023, 3:30 pm
Landmark clear outcomes study demonstrates nexletol® (bempedoic acid) tablet is the only ldl-c lowering therapy since statins to reduce hard ischemic events in a broad population of both primary preve
Results Demonstrate Significant Reductions in LDL-C, hsCRP and cardiovascular Risk in Patients Who Are ...
March 4, 2023, 3:30 pm
Landmark clear outcomes study demonstrates nexletol® (bempedoic acid) tablet is the only ldl-c lowering therapy since statins to reduce hard ischemic events in a broad population of both primary preve
Results Demonstrate Significant Reductions in LDL-C, hsCRP and cardiovascular Risk in Patients Who Are ...
March 4, 2023, 3:30 pm
Landmark clear outcomes study demonstrates nexletol® (bempedoic acid) tablet is the only ldl-c lowering therapy since statins to reduce hard ischemic events in a broad population of both primary preve
Results Demonstrate Significant Reductions in LDL-C, hsCRP and cardiovascular Risk in Patients Who Are ...
March 4, 2023, 3:30 pm
Landmark clear outcomes study demonstrates nexletol® (bempedoic acid) tablet is the only ldl-c lowering therapy since statins to reduce hard ischemic events in a broad population of both primary preve
Results Demonstrate Significant Reductions in LDL-C, hsCRP and cardiovascular Risk in Patients Who Are ...
March 4, 2023, 3:30 pm
Keros therapeutics reports recent business highlights and fourth quarter and full year 2022 financial results
LEXINGTON, Mass., March 03, 2023 (GLOBE NEWSWIRE) — Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage bio...
March 3, 2023, 9:01 pm
Verve therapeutics reports new preclinical data demonstrating potent and durable editing of angptl3 gene with verve-201 in wild-type and ldlr-deficient non-human primates
VERVE-201 Preclinical Data Supports Advancement of Drug Candidate Toward Clinical Development for Homozygous Familial Hypercholesterolemia, with Initi...
March 3, 2023, 11:30 am
